Understand the source comparison
Selank Amidate FAQ — Research Comparison Table
Researchers frequently compare Selank Amidate against standard Selank, other anxiolytic peptides like Semax Amidate, and nootropic compounds including Cerebrolysin and Dihexa. This comparison clarifies structural distinctions, stability profiles, and research
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers frequently compare Selank Amidate against standard Selank, other anxiolytic peptides like Semax Amidate, and nootropic compounds including Cerebrolysin and Dihexa. This comparison clarifies structural distinctions, stability profiles, and research application contexts.
- Selank Amidate
- 35–45 min
- GABAergic modulation + melanocortin receptor agonism
- 4–6% degradation/month at 2–8°C
- 100–600 mcg/kg subcutaneous
- Extended half-life reduces dosing frequency; acetyl modification provides measurable stability advantage for multi-week protocols
- Standard Selank
- 20–25 min
- GABAergic modulation + IL-6 regulation
- 8–12% degradation/month at 2–8°C
- 100–600 mcg/kg subcutaneous or intranasal
- Faster degradation requires more frequent reconstitution; suitable for short-duration studies where extended stability isn't critical
- Semax Amidate
- 30–40 min
- BDNF upregulation + melanocortin signaling
- 5–7% degradation/month at 2–8°C
- 200–1000 mcg/kg subcutaneous
- Nootropic focus vs anxiolytic; shares acetyl modification advantages; broader dose range reflects different receptor targets
- Cerebrolysin
- 4–6 hours (protein fragments)
- Neurotrophic factor mimetics
- Stable as manufactured for 36 months at 2–8°C
- 2.5–10 mL intramuscular
- Protein hydrolysate with distinct mechanism; pre-mixed formulation eliminates reconstitution variables but limits concentration customisation
- Dihexa
- 2–4 hours
- HGF/c-Met pathway activation
- 3–5% degradation/month at 2–8°C
- 1–5 mg/kg subcutaneous
- Non-peptide structure with different pharmacokinetics; cognitive enhancement mechanism unrelated to GABAergic pathways
- The comparison reveals that Selank Amidate occupies a specific research niche: anxiolytic and nootropic studies requiring dosing consistency across 4–12 week timelines where reconstitution frequency needs minimisation. Researchers studying acute anxiolytic responses in single-session designs won't benefit meaningfully from the amidate modification's extended stability. Standard Selank suffices when fresh reconstitution precedes each experimental session. The acetyl modification's value emerges in chronic administration models where maintaining consistent peptide concentration across weeks becomes the limiting variable for data interpretation.